ArticleClinical and translational allergy2026
Birch Rust Spore Exposure and Upper Airway Symptom Dynamics in a Subarctic Region: Indications for a Novel Seasonal Allergen.
Article in Clinical and translational allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05661812 (Norwegian Birch Rust Allergy Study. Allergy to Birch Rust Fungi, a Possible Explanation to Seasonal Airway Allergy During Autumn?), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Norwegian Birch Rust Allergy Study. Allergy to Birch Rust Fungi, a Possible Explanation to Seasonal Airway Allergy During Autumn?
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAirway allergies affect 20%-30% of the global population, with pollen and fungal spores representing major environmental triggers. Although fungal spores are far more abundant than pollen, their allergenic role-particularly from phytopathogenic rust fungi such as birch rust (BR)-remains poorly understood. In Northern Norway, where seasonal dispersal of BR spores occurs with minimal overlap from other aeroallergen exposures, we investigated their potential contribution to autumnal airway symptoms by linking spore distribution with clinical outcomes.
methodsIn this prospective study, 160 patients and 94 controls were followed during BR season (Aug-Oct) and out of season (Jan-Feb). Participants reported allergic rhinitis, conjunctivitis, and/or asthma. Symptom scores (Visual Analogue Scale), nasal airflow (Peak Nasal Inspiratory Flow), and lung function (spirometry) were recorded, alongside daily BR spore counts from three monitoring sites.
resultsDuring BR season, patients showed significantly higher symptom severity (VAS difference 1.58, p < 0.01) and lower PNIF values (-12.2 L/min, p = 0.01) versus controls. Seasonal increases in symptoms were observed (1.70, p < 0.001), and anti-allergic medication use was more frequent in patients (62.5% of patients vs. 1.1% of controls (p < 0.001). Symptom worsening was associated with reported proximity to birch forests (regression coefficient 0.46, p < 0.01, R
conclusionsBR spore exposure was associated with increased autumnal airway symptoms, suggesting that BR may represent an underrecognized trigger. These findings highlight the need for further research, including allergen-specific testing and dispersal modelling, to clarify their clinical relevance.
trial registrationThis study is registered at ClinicalTrials.gov (identifier: NCT05661812).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.